ADCT vs BMY · rev $40.1M vs P/E 17, rev $24.46B
ADC Therapeutics SA (ADCT) versus Bristol-Myers Squibb Company (BMY) — a side-by-side from cached financials, not a winner call.
ADC Therapeutics SA (ADCT) is a biotechnology company listed on NYSE.
Bristol-Myers Squibb Company (BMY) is a drug manufacturers - general company listed on US. It is led by Chris Boerner.
Latest reported ADCT revenue for 2026-06-30 was $40.1M. Net income was -$49.5M. Revenue was up 92.3% from 2026-03-31 to 2026-06-30. ADCT currently screens at market cap $141.2M.
Latest reported BMY revenue for 2026-06-30 was $24.46B. Net income was $5.99B. BMY currently screens at market cap $95.36B and trailing P/E 17.5.
ADCT currently screens at market cap $141.2M. BMY currently screens at market cap $95.36B and trailing P/E 17.5.
Not investment advice. Open the ADCT and BMY stock pages for the full models.
Not investment advice.